Filorexant

Drug Profile

Filorexant

Alternative Names: MK-6096

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Amides; Antidepressants; Antimigraines; Piperidines; Pyridines; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic neuropathies; Insomnia; Major depressive disorder; Migraine

Most Recent Events

  • 30 Aug 2015 No recent reports of development identified - Phase-II for Diabetic neuropathies in USA (PO)
  • 30 Aug 2015 No recent reports of development identified - Phase-II for Major depressive disorder (Adjunctive treatment, Recurrent) in USA (PO)
  • 30 Aug 2015 No recent reports of development identified - Phase-II for Migraine (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top